|
MY164523A
(en)
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
|
HUE033832T2
(en)
|
2002-11-15 |
2018-01-29 |
Idenix Pharmaceuticals Llc |
2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
|
|
EP2345657A1
(en)
|
2003-05-30 |
2011-07-20 |
Pharmasset, Inc. |
Modified fluorinated nucleoside analogues
|
|
AU2005285045B2
(en)
*
|
2004-09-14 |
2011-10-13 |
Gilead Sciences, Inc. |
Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
|
|
ES2381982T3
(es)
|
2004-11-16 |
2012-06-04 |
Thomson Licensing |
Método de simulación del grano de película basado en coeficientes de transformación previamente generados por ordenador
|
|
BRPI0517828A
(pt)
|
2004-11-16 |
2008-10-21 |
Thomson Licensing |
inserção de mensagens sei de grão de filme para uma simulação exata em bits em um sistema de vìdeo
|
|
ES2739452T3
(es)
|
2004-11-17 |
2020-01-31 |
Interdigital Vc Holdings Inc |
Método de simulación de grano de película con precisión de bits basado en coeficientes transformados calculados previamente
|
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
|
US10715834B2
(en)
|
2007-05-10 |
2020-07-14 |
Interdigital Vc Holdings, Inc. |
Film grain simulation based on pre-computed transform coefficients
|
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
|
PT2376088T
(pt)
|
2008-12-23 |
2017-05-02 |
Gilead Pharmasset Llc |
Fosforamidatos de nucleósidos de 2-amino-purina 6-osubstituída
|
|
SG194404A1
(en)
*
|
2008-12-23 |
2013-11-29 |
Gilead Pharmasset Llc |
Synthesis of purine nucleosides
|
|
KR20110098849A
(ko)
|
2008-12-23 |
2011-09-01 |
파마셋 인코포레이티드 |
뉴클레오시드 유사체
|
|
TWI598358B
(zh)
|
2009-05-20 |
2017-09-11 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
|
UY33312A
(es)
|
2010-03-31 |
2011-10-31 |
Pharmasset Inc |
Fosforamidato de nucleosido de purina
|
|
PL3290428T3
(pl)
|
2010-03-31 |
2022-02-07 |
Gilead Pharmasset Llc |
Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
|
|
PT2609923T
(pt)
|
2010-03-31 |
2017-08-30 |
Gilead Pharmasset Llc |
Processo para a cristalização de 2-(((s)- (perfluorofenoxi)(fenoxi)fosforil)amino)propanoato de (s)-isopropilo
|
|
JP5716500B2
(ja)
|
2010-06-03 |
2015-05-13 |
セントラル硝子株式会社 |
（２Ｒ）−２−フルオロ−２−Ｃ−メチル−Ｄ−リボノ−γ−ラクトン類前駆体の製造方法
|
|
AU2011336632B2
(en)
|
2010-11-30 |
2015-09-03 |
Gilead Pharmasset Llc |
Compounds
|
|
EP2691409B1
(en)
|
2011-03-31 |
2018-02-21 |
Idenix Pharmaceuticals LLC. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
|
TW201329096A
(zh)
|
2011-09-12 |
2013-07-16 |
Idenix Pharmaceuticals Inc |
經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物
|
|
PL2709613T5
(pl)
|
2011-09-16 |
2020-12-14 |
Gilead Pharmasset Llc |
Metody leczenia hcv
|
|
US8507460B2
(en)
|
2011-10-14 |
2013-08-13 |
Idenix Pharmaceuticals, Inc. |
Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
|
|
SE1450131A1
(sv)
|
2011-10-21 |
2014-05-07 |
Abbvie Inc |
DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV
|
|
US8466159B2
(en)
|
2011-10-21 |
2013-06-18 |
Abbvie Inc. |
Methods for treating HCV
|
|
DE112012002748T5
(de)
|
2011-10-21 |
2014-07-31 |
Abbvie Inc. |
Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
|
|
US8492386B2
(en)
|
2011-10-21 |
2013-07-23 |
Abbvie Inc. |
Methods for treating HCV
|
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
|
CA2873315A1
(en)
|
2012-05-22 |
2013-11-28 |
Idenix Pharamaceuticals, Inc. |
D-amino acid compounds for liver disease
|
|
WO2013177188A1
(en)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
3',5'-cyclic phosphoramidate prodrugs for hcv infection
|
|
US9296778B2
(en)
|
2012-05-22 |
2016-03-29 |
Idenix Pharmaceuticals, Inc. |
3′,5′-cyclic phosphate prodrugs for HCV infection
|
|
SG11201407336PA
(en)
|
2012-05-25 |
2015-03-30 |
Janssen Sciences Ireland Uc |
Uracyl spirooxetane nucleosides
|
|
CN104379591A
(zh)
|
2012-05-29 |
2015-02-25 |
弗·哈夫曼-拉罗切有限公司 |
用于制备2-脱氧-2-氟-2-甲基-d-呋喃核糖基核苷化合物的方法
|
|
CN103450148B
(zh)
*
|
2012-06-04 |
2018-06-12 |
浙江九洲药业股份有限公司 |
一种五元环硫酸酯化合物的合成方法
|
|
WO2014052638A1
(en)
|
2012-09-27 |
2014-04-03 |
Idenix Pharmaceuticals, Inc. |
Esters and malonates of sate prodrugs
|
|
KR102001280B1
(ko)
|
2012-10-08 |
2019-07-17 |
아이데닉스 파마슈티칼스 엘엘씨 |
Hcv 감염에 대한 2'-클로로 뉴클레오시드 유사체
|
|
CN103724301A
(zh)
*
|
2012-10-10 |
2014-04-16 |
上海特化医药科技有限公司 |
(2r)-2-脱氧-2,2-二取代-1,4-核糖内酯及其制备方法和用途
|
|
WO2014066239A1
(en)
|
2012-10-22 |
2014-05-01 |
Idenix Pharmaceuticals, Inc. |
2',4'-bridged nucleosides for hcv infection
|
|
EP2935304A1
(en)
|
2012-12-19 |
2015-10-28 |
IDENIX Pharmaceuticals, Inc. |
4'-fluoro nucleosides for the treatment of hcv
|
|
CN103012386B
(zh)
*
|
2012-12-26 |
2015-04-01 |
浙江普洛得邦制药有限公司 |
一种五元环状硫酸酯的制备方法
|
|
PT2950786T
(pt)
|
2013-01-31 |
2020-03-03 |
Gilead Pharmasset Llc |
Formulação de combinação de dois compostos antivirais
|
|
US10034893B2
(en)
|
2013-02-01 |
2018-07-31 |
Enanta Pharmaceuticals, Inc. |
5, 6-D2 uridine nucleoside/tide derivatives
|
|
US9309275B2
(en)
|
2013-03-04 |
2016-04-12 |
Idenix Pharmaceuticals Llc |
3′-deoxy nucleosides for the treatment of HCV
|
|
US9339541B2
(en)
|
2013-03-04 |
2016-05-17 |
Merck Sharp & Dohme Corp. |
Thiophosphate nucleosides for the treatment of HCV
|
|
WO2014160484A1
(en)
|
2013-03-13 |
2014-10-02 |
Idenix Pharmaceuticals, Inc. |
Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
|
|
EP2981542B1
(en)
|
2013-04-01 |
2021-09-15 |
Idenix Pharmaceuticals LLC |
2',4'-fluoro nucleosides for the treatment of hcv
|
|
US10005779B2
(en)
|
2013-06-05 |
2018-06-26 |
Idenix Pharmaceuticals Llc |
1′,4′-thio nucleosides for the treatment of HCV
|
|
WO2015017713A1
(en)
|
2013-08-01 |
2015-02-05 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
|
|
EA201690473A1
(ru)
|
2013-08-27 |
2017-03-31 |
ГАЙЛИД ФАРМАССЕТ ЭлЭлСи |
Комбинированный состав двух противовирусных соединений
|
|
CN104447923B
(zh)
*
|
2013-09-23 |
2018-03-30 |
中国药科大学 |
2’‑脱氧‑2’‑氟‑2’‑甲基核苷衍生物及其制备方法与在制药中的用途
|
|
WO2015161137A1
(en)
|
2014-04-16 |
2015-10-22 |
Idenix Pharmaceuticals, Inc. |
3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
|
|
US9675632B2
(en)
|
2014-08-26 |
2017-06-13 |
Enanta Pharmaceuticals, Inc. |
Nucleoside and nucleotide derivatives
|
|
WO2016042576A1
(en)
|
2014-09-16 |
2016-03-24 |
Cadila Healthcare Limited |
Co-crystal of sofosbuvir and amino acid and process for preparation thereof
|
|
CN104744539A
(zh)
*
|
2014-09-19 |
2015-07-01 |
上海皓元生物医药科技有限公司 |
一种(2’r)-2’-脱氧-2’-氟-2’-甲基脲苷的合成方法
|
|
CN104327138B
(zh)
*
|
2014-10-21 |
2017-05-10 |
齐鲁制药有限公司 |
Psi‑7977中间体化合物的制备方法
|
|
WO2016073756A1
(en)
|
2014-11-06 |
2016-05-12 |
Enanta Pharmaceuticals, Inc. |
Deuterated nucleoside/tide derivatives
|
|
US9732110B2
(en)
|
2014-12-05 |
2017-08-15 |
Enanta Pharmaceuticals, Inc. |
Nucleoside and nucleotide derivatives
|
|
CN104610404B
(zh)
*
|
2015-01-16 |
2016-04-06 |
南通常佑药业科技有限公司 |
一种呋喃核糖磷酸酯衍生物的制备方法
|
|
CA3182565A1
(en)
|
2015-03-06 |
2016-09-15 |
Atea Pharmaceuticals, Inc. |
.beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
|
|
CN104829672B
(zh)
*
|
2015-05-19 |
2018-03-13 |
江苏福瑞生物医药有限公司 |
一种药物中间体的合成方法
|
|
CN105061535A
(zh)
*
|
2015-09-02 |
2015-11-18 |
江苏科本医药化学有限公司 |
一种索非布韦中间体的合成方法
|
|
CN106554333B
(zh)
*
|
2015-09-29 |
2018-11-30 |
江苏福瑞生物医药有限公司 |
一种药物中间体的合成方法
|
|
CN106608896B
(zh)
*
|
2015-10-26 |
2019-08-27 |
江苏福瑞康泰药业有限公司 |
一种药物中间体的合成方法
|
|
CN105418547A
(zh)
*
|
2015-11-17 |
2016-03-23 |
海门慧聚药业有限公司 |
索非布韦关键中间体的制备
|
|
CN105503983B
(zh)
*
|
2015-12-17 |
2019-06-28 |
江苏阿尔法药业有限公司 |
索菲布韦中间体及其衍生物的制备方法
|
|
CN105566422B
(zh)
*
|
2015-12-29 |
2019-06-25 |
江苏阿尔法药业有限公司 |
索菲布韦中间体或其衍生物的制备方法
|
|
EA201892448A1
(ru)
|
2016-04-28 |
2019-06-28 |
Эмори Юниверсити |
Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
|
|
US10711029B2
(en)
|
2016-07-14 |
2020-07-14 |
Atea Pharmaceuticals, Inc. |
Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
|
|
US10239910B2
(en)
|
2016-07-20 |
2019-03-26 |
Optimus Drugs (P) Limited |
Process for the preparation of sofosbuvir
|
|
DK3512863T3
(da)
|
2016-09-07 |
2022-03-07 |
Atea Pharmaceuticals Inc |
2¿-substituerede-N6-substituerede purinnukleotider til behandling af RNA-virus
|
|
CN115477679A
(zh)
|
2017-02-01 |
2022-12-16 |
阿堤亚制药公司 |
用于治疗丙型肝炎病毒的核苷酸半硫酸盐
|
|
CN106810515A
(zh)
*
|
2017-02-06 |
2017-06-09 |
抚州市星辰药业有限公司 |
一种合成索非布韦的中间体化合物及其合成方法
|
|
CN109422789A
(zh)
*
|
2017-08-28 |
2019-03-05 |
常州制药厂有限公司 |
一种索非布韦的制备工艺改进方法
|
|
EP3773753A4
(en)
|
2018-04-10 |
2021-12-22 |
ATEA Pharmaceuticals, Inc. |
TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
|
|
CN108675984A
(zh)
*
|
2018-06-22 |
2018-10-19 |
江苏阿尔法药业有限公司 |
索非布韦中间体的制备方法
|
|
CN111606961A
(zh)
*
|
2019-02-26 |
2020-09-01 |
顾世海 |
一种(2’r)-2’-脱氧-2’-氟-2’-甲基脲苷的工艺生产方法
|
|
CN111040010A
(zh)
*
|
2019-12-23 |
2020-04-21 |
上海红蓝医药科技有限公司 |
一种索非布韦中间体的合成方法
|
|
US10874687B1
(en)
|
2020-02-27 |
2020-12-29 |
Atea Pharmaceuticals, Inc. |
Highly active compounds against COVID-19
|
|
KR20240022574A
(ko)
|
2021-06-17 |
2024-02-20 |
아테아 파마슈티컬즈, 인크. |
유리한 항-hcv 조합 요법
|